منابع مشابه
Age estimation using level of eyebrow and eyelash whitening
BACKGROUND The aim of this study was to determine whether eyebrow and eyelash whitening is an effective parameter in age estimation. MATERIAL AND METHODS We evaluated 1545 patients. Age groups were 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, and 81-90 years. Level of whitening was categorized as level 0: no whitening, level 1: 1-3 strands, level 2: 3-10 strands, level 3: 10 strands...
متن کاملTranspalpebral eyebrow lift: the mini eyebrow lift
Aim: This paper focus is to describe and evaluate the authors' personal technique for a simplified transpalpebral eyebrow lift. Methods: We performed surgery in 179 patients (95% females and 5% males) between years of 2008 and 2009. Initially, a thorough assessment of brow stability and symmetry was performed. To achieve desirable aesthetic we agreed upon the consensus that the eyebrow lateral ...
متن کاملImatinib-Induced Psoriasis
Imatinib is a signal transduction regulator that selectively inhibits the tyrosine kinase family, including bcr-abl and c-kit, and the platelet-derived growth factor (PDGF) receptor. It is currently the fi rst-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients [1]. We report the case of a patient who had no previous history of psoriasis but developed psoriasis after starti...
متن کاملReshaping the eyebrow by follicular unit transplantation from excised eyebrow in extended infrabrow excision blepharoplasty
PURPOSE We report the reshaping of the eyebrow by follicular unit transplantation from excised eyebrow skin in extended infrabrow excision blepharoplasty. METHODS The method was carried out in two patients with moderate or significant dermatochalasis. The areas to be excised from the infrabrow and intrabrow skin were decided upon and the area of hair transplantation was planned in the suprabr...
متن کاملProteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibitors. The synthesis of a new series of phenylaminopyrimidines, structurally related to imatinib, s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Trichology
سال: 2020
ISSN: 0974-7753
DOI: 10.4103/ijt.ijt_83_19